Pharma BD Deal Intelligence
GSK paid $720M for an unvalidated sirtuin/resveratrol platform that was clinically abandoned within 2 years and organizationally dissolved within 5 — a textbook case of buying hype without independent scientific validation.
Full analysis, sources & comparables →GSK paid $22.50/share — a roughly 82% premium — for Sirtris's sirtuin platform, with lead SRT501 in Phase 2a in Type 2 diabetes plus Phase 1b work in MELAS and…
Independent Pfizer and Amgen studies in 2009–2010 showed resveratrol did not directly activate SIRT1 — the apparent effects were experimental artifacts from…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$22.50/share cash; sirtuin platform, SRT501
GSK paid $720M for an unvalidated sirtuin/resveratrol platform that was clinically abandoned within 2 years and organizationally dissolved within 5 — a textbook case of buying hype without independent scientific validation.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / Sirtris Pharmaceuticals, Inc. (this deal) | 2008 | $720M | 9 |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
← Browse all deals · How we score deals
More: 2008 deals · GlaxoSmithKline plc deals